Novartis receives World Health Organization prequalification for new Coartem dosage

16 July 2015
novartis-basel-big

Swiss pharma major Novartis (NOVN: VX) has received World Health Organization (WHO) prequalification for its Coartem 80/480mg (artemether and lumefantrine).

This makes it the first and only high strength artemisinin-based combination therapy (ACT) antimalarial treatment available for public sector procurement. The new dosage strength has the potential to improve malaria management. The WHO prequalification now allows for large-scale public sector procurement which would possibly provide access to the treatment to up to 25 million malaria sufferers in Africa.

Joseph Jimenez, chief executive of Novartis, said: "Over the last ten years, Novartis has worked with partners to make Coartem treatments available to patients in the public sector and through donor-funded private sector programs. WHO prequalification of Coartem 80/480mg aligns with the longstanding work of the Novartis Malaria Initiative and confirms the company's status as a leading innovator in malaria treatment."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical